ArticleMicrobiology spectrum2026
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Delafloxacin (DLX) is a novel fluoroquinolone (FQ) with enhanced activity against gram-positive bacteria and under acidic conditions. Since the pH of urine is usually acidic, DLX could be an alternative to current drugs for urinary tract infections (UTIs), especially in male patients, for whom good prostatic tissue penetration is required. The aim of this study was to evaluate IMPORTANCE: Enterococci urinary tract infections (UTIs) are common but often difficult to treat in male patients, in whom good prostatic tissue penetration is required. Fluoroquinolones (FQs) remain attractive in this setting even though their efficacy is altered by the acidic pH of urine. Delafloxacin (DLX) is a novel FQ whose structure confers enhanced activity against gram-positive bacteria and under acidic conditions such as urine. Here, we demonstrate that DLX is substantially more active
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.